

2018

Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1

Morgan E. Freret

Washington University School of Medicine in St. Louis

Corina Anastasaki

Washington University School of Medicine in St. Louis

David H. Gutmann

Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Freret, Morgan E.; Anastasaki, Corina; and Gutmann, David H., "Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1." *Neurology Genetics*.4,4. e261. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7090

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Independent *NF1* mutations underlie café-au-lait macule development in a woman with segmental *NF1*

Morgan E. Freret, PhD, Corina Anastasaki, PhD, and David H. Gutmann, MD, PhD

Neurol Genet 2018;4:e261. doi:10.1212/NXG.0000000000000261

Correspondence

Dr. Gutmann
gutmann@wustl.edu

Segmental neurofibromatosis type 1 (*NF1*) is an under-recognized form of *NF1* caused by postzygotic somatic loss-of-function *NF1* gene mutations that affect a subset of cells in the body.¹ This is in contrast to classic or generalized *NF1*, in which a germline *NF1* gene mutation affects all diploid cells in the body. In the segmental *NF1* variant, individuals typically exhibit clinical features characteristic of generalized *NF1*, such as café-au-lait macules (CALMs), skinfold freckling, and neurofibromas, restricted to one segment of the body. For this reason, establishing the diagnosis can be challenging because the underlying *NF1* gene mutation is often not detected in the blood. Underscoring the challenges of caring for individuals with this variant of *NF1*, we describe a woman with segmental *NF1* referred to us at 22 years of age for evaluation.

The patient first came to medical attention at four months of age when her pediatrician noted that she had more than six CALMs localized to her right abdomen, back, and hip. Over the next five years, she developed additional hyperpigmented macules in this region, followed by freckling in the right inguinal region. Collectively, these findings met the criteria for a diagnosis of segmental *NF1*. On examination, the CALMs and skinfold freckling in the affected region did not cross either the anterior or posterior midlines, and there were no neurofibromas, other hyperpigmented lesions, or Lisch nodules detected. Because the affected body segment could potentially include her right ovary, at 28 years of age, she underwent genetic testing (direct Sanger sequencing, mixed ligation-dependent probe amplification, and interphase fluorescence in situ hybridization [FISH]), which failed to identify an *NF1* gene mutation in her blood. She subsequently underwent biopsy of three of her CALMs (right lower back, hip, and abdomen), followed by primary culture of these skin melanocytes for genetic testing as above.² As shown in the figure, sequencing and FISH revealed that all three CALM-derived melanocyte cultures shared a common 1.4 megabase deletion of the *NF1* gene (type 1 total gene deletion [TGD]). Furthermore, in each of the three CALMs, a different second-hit mutation was identified that affected the remaining (non-deleted) *NF1* gene copy.

This case report is instructive for several reasons. First, it underscores the utility of analyzing the affected tissues (e.g., melanocytes from multiple CALMs), rather than the blood, in establishing a diagnosis of segmental *NF1*. Although this patient met the diagnostic criteria for segmental *NF1* on clinical grounds (regional distribution of CALMs and inguinal freckling), the genetic findings provide a reference for future prenatal genetic counseling and diagnostic testing.³ Second, genetic testing of affected tissue suggests that this patient sustained a total *NF1* gene deletion during post-zygotic development and thus affected only a subset of her cells. Individuals with the generalized form of *NF1* who harbor this type of mutation (type 1 TGD) frequently have a more severe phenotype, with greater numbers of neurofibromas and an increased risk of cancer, compared with individuals with generalized *NF1* caused by other *NF1* gene mutations.⁴ By contrast, this patient with segmental *NF1* has no visible neurofibromas and is otherwise healthy, which is different from a previous report of several patients with segmental


From the Department of Neurology (M.E.F., C.A., D.H.G.), Washington University School of Medicine, Saint Louis, MO; and Harvard Medical School (M.E.F.), Boston, MA.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

The Article Processing Charge was funded by NIH.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Figure Unique second neurofibromatosis type 1 (*NF1*) gene mutations in multiple café-au-lait macules (CALMs) from an individual with segmental *NF1*



(A) Segmental or mosaic *NF1* is caused by de novo *NF1* gene mutations that occur during postzygotic development and affect only a subset of cells in the body. Genetic testing of melanocytes derived from three different CALMs in the patient's affected body segment (denoted by the diagonal stripes) revealed a common 1.4 megabase (MB) deletion, resulting in total loss of one copy of the *NF1* gene, and three unique second-hit mutations affecting the remaining *NF1* allele. The insets depict both *NF1* gene copies in the indicated cell types. (B) Locations (colored pinheads) and predicted messenger RNA (mRNA) and protein changes resulting from the second *NF1* gene mutations in melanocytes derived from three different CALMs. Two intronic mutations were located within splice sites, and one exonic mutation resulted in a premature stop codon (nonsense mutation). Short black boxes denote introns; tall gray boxes denote exons.

NF1 and type 1 TGDs.⁵ In that series, four of the five cases had either numerous dermal neurofibromas or a plexiform neurofibroma. The less severe phenotype in the current subject suggests that, compared with previously reported cases, (1) her total *NF1* gene deletion may have arisen at a later developmental stage, (2) it is restricted to a different population of cells, or (3) modifier genes additionally influence clinical expression. Third, each of the CALMs in this patient contained melanocytes harboring a unique second *NF1* gene mutation that presumably resulted in loss of or impaired function of the *NF1*-encoded protein (neurofibromin) in those cells. This finding is consistent with previous reports demonstrating biallelic *NF1* gene inactivation in CALMs,^{6,7} similar to that observed in benign tumors from patients with *NF1*.² The finding that the second-hit mutations were distinct in each CALM argues that each macule arose independently, similar to benign

neoplasms (i.e., neurofibromas) that arise in this population of tumor-prone individuals.

Author contributions

M.E. Freret contributed to manuscript preparation and made the figure. C. Anastasaki contributed to manuscript preparation. D.H. Gutmann wrote the first draft of the manuscript.

Study funding

This work was supported by the NIH (1-R35-NS07211-01, D.H. Gutmann).

Disclosure

M.E. Freret and C. Anastasaki report no disclosures. D.H. Gutmann holds patents for the identification of the *ND1* gene and mTOR regulator; has received research support from the US Army Department of Defense, the Giorgio Foundation,

the Children's Tumor Foundation, and the Neurofibromatosis Acceleration Therapeutics Program; receives license fee payments for the TSC1 knockout mouse; and receives royalty payments for the NF1 gene patent. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Received March 20, 2018. Accepted in final form April 24, 2018.

References

1. Listernick R, Mancini AJ, Charrow J. Segmental neurofibromatosis in childhood. *Am J Med Genet A* 2003;121A:132–135.
2. Maertens O, De Schepper S, Vandesompele J, et al. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. *Am J Hum Genet* 2007;81:243–251.
3. Ko Y, Lee C, Lee H, Lee M, Lee JS. Clinical application of next-generation sequencing for the diagnosis of segmental neurofibromatosis. *J Dermatol Sci* 2017;88:370–372.
4. Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype-phenotype relationships in patients with large NF1 deletions. *Hum Genet* 2017;136:349–376.
5. Messiaen L, Vogt J, Bengesser K, et al. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). *Hum Mutat* 2011;32:213–219.
6. Eisenbarth I, Assum G, Kaufmann D, Krone W. Evidence for the presence of the second allele of the neurofibromatosis type 1 gene in melanocytes derived from cafe au lait macules of NF1 patients. *Biochem Biophys Res Commun* 1997;237:138–141.
7. De Schepper S, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L. Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes. *J Invest Dermatol* 2008;128:1050–1053.

Neurology[®] Genetics

Independent *NF1* mutations underlie café-au-lait macule development in a woman with segmental NF1

Morgan E. Freret, Corina Anastasaki and David H. Gutmann

Neurol Genet 2018;4;

DOI 10.1212/NXG.0000000000000261

This information is current as of July 23, 2018

Updated Information & Services	including high resolution figures, can be found at: http://ng.neurology.org/content/4/4/e261.full.html
References	This article cites 7 articles, 0 of which you can access for free at: http://ng.neurology.org/content/4/4/e261.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Clinical Neurology http://ng.neurology.org/cgi/collection/all_clinical_neurology All Genetics http://ng.neurology.org/cgi/collection/all_genetics Neurofibromatosis http://ng.neurology.org/cgi/collection/neurofibromatosis
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://ng.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://ng.neurology.org/misc/addir.xhtml#reprintsus

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.

